Dr Alan Walker : Chief Executive Officer
Alan is an experienced CEO with 51 years' experience in big and small pharma and biotech. He spent 28 years in Warner Lambert and 8 years as commercial head of ProStrakan before becoming joint (co founder) CEO Internis until exit. Recently Alan was CEO of Ryboquin the gene engineering company and Nanogenics acquired by Ryboquin.
Prof. W. H. Stimson FRSE: Chief Scientific Officer
Bill is the founder of the Department of Immunology at The University of Strathclyde. He has been involved in eight start-up/spin-out biotech companies. He has been a long -term consultant to five multinational companies including Akzo Nobel, Rhone-Poulenc and Johnson & Johnson. Bill has published 215 scientific papers and 25 patents. He was involved in the use of the first human monoclonal antibodies for cancer therapy.
Dr Magnus Nicolson MBA FRSC FRSM : Chairman
Magnus has been a CEO, COO and General Manager of Life Science companies in Europe the US and the Gulf. As COO he listed a company on AMEX. Several small companies he ran have been sold to leading multinationals. He has degrees in Biochemistry, Immunology (MSc &PhD) and an MBA and has taken products all the way from the laboratory to market.
Kevin is a serial technology entrepreneur with over 30 years experience. He has successfully established and exited a number of technology businesses. Kevin established the EOS Technology Investment Syndicate in 2014 which is a group of private angel investors focused on early stage science and technology opportunities.
Hazel is a chartered accountant, business performance coach and financial engineer of over 20 years’ experience. She has strong commercial and strategic experience including roles at the University of the Highlands and Islands, National Semiconductor Corp & PwC and holds non-executive Director roles in research and commercial organisations.
Peter has over three decades of experience in the pharmaceutical and pharmaceutical and biotech industry including senior strategic and operational roles in a 20+ year career with GSK. He more recently served as CEO of Syngene (where he led a successful IPO and listing) and Sosei Heptares, a Japanese publicly listed company.
Richard has played an active role in the development of over 35 life science companies assisting a number of these with listings on the London Stock Exchange.
ILC Therapeutics™ is supported by a Scientific Advisory Board with experts and practitioners from industry and academia as well as a number of other highly experienced business professionals.
Scientific Advisory Board
Professor Kathryn Ball – Professor of Biochemistry & Cell Signalling at the Institute of Genetics and Molecular Medicine at the University of Edinburgh
Professor Ted Hupp – Chair of Experimental Cancer Research at the University of Edinburgh
Professor Alex Mullen – Professor of Pharmacy Practice at the University of Strathclyde
Dr Cathy Adamson - Lecturer in Molecular Medicine at the University of St Andrews
Chris Brinsmead, CBE – council member at Imperial College London, former advisor to the UK Government on life sciences with a career consisting of many senior Executive and Non-Executive roles
Dr Elisabeth Vokurka – an IP strategy consultant with extensive experience in intellectual property management and supporting SME’s
Allan Watson – experienced public company CFO with a pharma and med-tech background and extensive M&A experience